11:54 AM EST, 11/15/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that interim analysis of two-and-a-half-year data from the ongoing Assure phase 3 study of Livdelzi, also known as seladelpar, showed that the majority of participants with primary biliary cholangitis or PBC achieved a composite biochemical response.

The biopharmaceutical company said 81% of the study's participants achieved durable biochemical response by month 30, with "significant improvements" in key measures of disease progression.

Gilead Sciences ( GILD ) also noted that 41% of patients under the study achieved normalization of alkaline phosphatase levels, which is a critical biomarker of liver function.

Gilead Sciences ( GILD ) said the ongoing Assure phase 3 study is targeting to enroll up to 500 patients with PBC across 160 sites globally.

Price: 89.64, Change: -2.47, Percent Change: -2.68